

1 **Title:**

2 Estimating the optimal age for infant measles vaccination

3

4 **Authors:**

5 Elizabeth Goult^{1,*}

6 Laura Andrea Barrero Guevara ^{1,2}

7 Michael Briga¹

8 Matthieu Domenech de Cellès¹

9

10 1. Infectious Disease Epidemiology group, Max Planck Institute for Infection Biology,
11 Charitéplatz 1, Campus Charité Mitte, 10117, Berlin, Germany

12 2. Institute of Public Health, Charité—Universitätsmedizin Berlin, 10117, Berlin,
13 Germany

14

15 * Corresponding author, email: goult@mpiib-berlin.mpg.de

16

17 **Abstract:** (150 words)

18 The persistence of measles in many regions demonstrates large immunity gaps, resulting from
19 incomplete or ineffective immunization with measles-containing vaccines (MCVs). A key
20 factor affecting MCV impact is age, with infants receiving dose 1 (MCV1) at older ages having
21 a reduced risk of vaccine failure, but also an increased risk of contracting infection before
22 vaccination. Here, we designed a new method—based on a transmission model incorporating
23 realistic vaccination delays and age variations in MCV1 effectiveness—to capture this risk
24 trade-off and estimate the optimal age for recommending MCV1. We predict a large
25 heterogeneity in the optimal ages (range: 6–20 months), contrasting the homogeneity of
26 observed recommendations worldwide. Furthermore, we show that the optimal age depends on
27 the local epidemiology of measles, with a lower optimal age predicted in populations suffering
28 higher transmission. Overall, our results suggest the scope for public health authorities to tailor
29 the recommended schedule for better measles control.

30

31 **Main text:** (4992 words)

32 **Introduction:** (724 words)

33 Measles is a highly contagious childhood infection¹ caused by the measles virus. The virus is
34 primarily spread through respiratory droplets and aerosols², and symptoms include cough,
35 fever, malaise, and a characteristic maculopapular rash¹. Historically, measles was a major
36 childhood disease, infecting almost all individuals in early life³ and resulting in 2–3 million
37 deaths per year¹. The introduction of measles vaccines in the 1960s significantly reduced the
38 global number of measles cases and deaths⁴, with estimated deaths in 2021 reduced to
39 approximately 128,000⁵.

40

41 However, despite the indisputable global success of the vaccine, measles remains endemic in
42 multiple countries. Many regional elimination targets for 2020 were not met⁶, reflecting the
43 difficulty of reaching the high immunization coverage needed for measles elimination⁴. These
44 difficulties were compounded during the COVID-19 pandemic, which caused interruptions in
45 routine vaccinations and supplementary immunization activities (SIAs)^{6,7}, resulting in new
46 measles outbreaks in 18 countries⁶. Since 2020, 140 countries have reported at least 1 case per
47 year to the World Health Organization (WHO), and over 30 countries have reported over 1,000
48 cases in a year⁸.

49

50 Although the immunity gaps that drive continued measles transmission are mainly caused by
51 insufficient vaccine coverage, they also result from vaccine failures. One avertable cause of
52 these vaccine failures is the vaccination age: vaccination with the first dose of measles-
53 containing vaccine (MCV1) at younger ages results in a higher risk of vaccine failure⁹. Two
54 main mechanisms have been proposed to explain this result: blunting by maternal antibodies
55 and immaturity of the infant immune system^{10,11}. However, despite the potential consequences

56 on measles control – e.g., changing the recommended MCV1 age as a potential control
57 intervention – the impact of vaccination age on vaccine effectiveness (VE) has only recently
58 been quantified⁹.

59

60 As illustrated in Figure 1a, the increasing effectiveness of MCV1 with age should result in a
61 trade-off in risks when recommending MCV1 age: reducing the age of vaccination increases
62 the risk of vaccine failure, while increasing the age worsens the risk of infection before
63 vaccination. Hence, by balancing these risks, the recommended MCV1 age may be optimized
64 to minimize measles incidence. Furthermore, location-specific factors, such as transmission
65 level, are expected to affect this trade-off by changing the mean age of infection (MAI),
66 resulting in different optimal ages^{12,13}. Following this conceptual model, one expects the
67 optimal vaccination age to depend on the local epidemiology of measles.

68

69 As seen in Figure 2, however, the global homogeneity in recommended MCV1 ages contrasts
70 with the observed heterogeneity in measles incidence¹⁴. The partial Spearman rank correlation
71 coefficient between MCV1 ages and countries' mean annual incidence was only -0.12 (p -
72 value: 0.53) in countries with ≥ 1 measles case per 1 million per year, when controlling for
73 Human Development Index (HDI), an aggregate measure of countries' longevity, education,
74 and standard of living¹⁵. Of the 205 MCV1 recommendations obtained, 70% of
75 recommendations were at 9 months (69 countries) or 12 months (109 countries), reflecting the
76 recommendations from the WHO: MCV1 at 9 months in countries with ongoing transmission
77 and at 12 months in countries with low transmission¹⁴. Although these recommendations
78 generally reflect the trade-off in risks, they may not capture the complexity of factors that
79 impact measles epidemiology, such as further transmission variation driven by differences in
80 social contact patterns or vaccination coverage.

81

82 The relative homogeneity in MCV1 recommendations suggests opportunities for refining the
83 MCV1 age to leverage this risk trade-off. Here, we propose a new method—based on a
84 mechanistic model of endemic measles transmission incorporating realistic, data-driven
85 models of MCV1 delay and VE variation with age—to estimate the optimal age to recommend
86 MCV1. As a proof of concept, we used this method to estimate the optimal MCV1 age in a
87 range of synthetic test populations. In these populations, we varied parameter values across
88 realistic ranges to identify factors determining optimal age (Figure 1b). We show that a
89 mismatch between the optimal and recommended ages can potentially increase measles
90 incidence. Furthermore, we show that the optimal age is sensitive to location-specific
91 determinants of measles epidemiology, with transmission level having the greatest effect,
92 followed by the social contact structure and vaccination coverage. Overall, our study suggests
93 that the optimal MCV1 age is highly population-specific and, hence, more heterogeneous than
94 the current recommendations reflect. Our findings thus suggest the potential to adjust MCV1
95 ages to reduce measles incidence, taking steps toward eventual elimination.

96

97 **Methods:** (1,453 words)

98 Data on measles incidence, recommended MCV1 age, and the Human Development Index

99 We gathered data on MCV1 recommended age from the WHO¹⁶ and the European Centre for
100 Disease Prevention and Control (ECDC)¹⁷, supplemented with reports from individual
101 countries in cases of missing data^{18–23}. We also collected country-level estimates of annual
102 measles incidence for 2010–2019 from the WHO¹² and HDI values for the same period from
103 the United Nations Development Program¹⁵.

104

105 The relationship between MCV age and vaccine effectiveness

106 To quantify how vaccination age affects MCV VE, we fitted a statistical model to reported
107 estimates of MCV VE, obtained from a systematic review⁹. For MCV1 VE, to reduce
108 uncertainty in MCV1 age, we only included estimates with an MCV1 age interval of <3
109 months. For the included MCV1 VE estimates, we calculated each estimate's standard error
110 from reported 95% confidence intervals²⁴.

111

112 We then fitted a shape-constrained additive model (SCAM)²⁵ to the logit-transformed MCV1
113 VE estimates. Specifically, we used a monotonically increasing P-spline basis with 4 knots,
114 weighted according to precision, with standard errors transformed using the Delta method. We
115 then calculated approximate simultaneous confidence intervals to assess uncertainty in model
116 fit²⁶. To include this uncertainty in the transmission model, we considered 5 curves
117 corresponding to the predicted 2.5%, 25%, 75%, and 97.5% quantiles and the maximum
118 likelihood estimate (MLE) from the SCAM.

119

120 For MCV dose 2 (MCV2) VE, too few estimates were available to assess age dependencies
121 (Supplementary Figure 1). We, therefore, assumed MCV2 VE to be constant and equal to the
122 mean MCV2 VE.

123

124 The distribution of MCV1 delay

125 To incorporate realistic distributions of MCV delay (*i.e.*, the delay between the recommended
126 age and the actual age of administration), we obtained data on MCV1 delay in 45 low and
127 middle-income countries (LMICs)²⁷, where most measles deaths occur⁵. The data consisted of
128 the observed 25%, 50%, and 75% quantiles of the delay distribution. We excluded any
129 countries with negative median delay. We initially fitted an Exponential distribution, which
130 failed to capture the observed long right tails. Hence, we then fitted a Lomax distribution²⁸ (an

131 extension of the Exponential distribution with longer right tails to capture long delays) to every
132 country by minimizing the squared distance between the simulated and observed quantiles. To
133 summarize the variation in delay distributions, we clustered the Lomax distribution parameters
134 using Partitioning Around Medoids (PAM) Euclidean distance clustering²⁹. The number of
135 clusters was determined using the average silhouette method³⁰ and the Gap statistic³¹, with 500
136 bootstraps.

137

138 Model of measles transmission and vaccination

139 To simulate measles incidence when recommending MCV1 at different ages, we constructed a
140 mechanistic model of measles transmission and vaccination, incorporating the aforementioned
141 data-driven statistical models of MCV1 delay and age-specific MCV1 VE. The model was a
142 deterministic SIR model, which split the population by infection status into susceptible,
143 infectious, recovered, and protected by maternal antibodies. For sufficiently large populations,
144 deterministic models have been shown to capture the dynamics of measles^{32,33}.

145

146 The model was age-structured, to allow the vaccination age to vary. The model split the
147 population into monthly age groups between ages 0 to 59 months, then into 5-year age groups
148 between ages 5 to 79. We assumed a uniform age distribution and constant population size.
149 Contacts between age groups were parameterized using data-derived social contact matrices
150 (SCM)^{34,35}. To capture the variability in social contact structure, we selected 7 SCMs derived
151 from China, India, Japan, Moscow, South Africa, the UK, and the USA, representing the
152 clusters identified in a previous study that clustered SCMs from 35 countries and 277
153 subnational administrative regions³⁴.

154

155 To model vaccination with two doses of MCV, we added a vaccinated susceptible state to
156 model infants with primary vaccine failure (*i.e.*, infants who received the vaccine but failed to
157 mount an effective immune response³⁶). Vaccination was assumed to occur when aging from
158 one age group to the next. For the first dose (MCV1), at a given age, individuals were either
159 vaccinated or not vaccinated, determined by the recommended MCV1 age, delay distribution,
160 and MCV1 coverage. If unvaccinated, individuals entered the next age group's susceptible
161 compartment. If vaccinated, the probability of successful vaccination was determined by the
162 VE-age relationship. If successful, infants were protected and entered the recovered
163 compartment of the next age group. If unsuccessful, they remained unprotected and entered the
164 next age group's vaccinated-susceptible compartment. The process remained the same for
165 MCV2, but vaccination occurred when aging from the vaccinated susceptible compartment.
166 The recommended MCV2 age was modeled as 6 months after the recommended MCV1 age,
167 aligning with the modal gap between reported MCV schedules^{16–23}.

168

169 Full model details, including parameterization, are included in the supplementary materials
170 (Supplementary Table 1).

171

172 Recapitulating reported pre-vaccine mean ages of measles infection

173 To calibrate transmission parameters, we compared the simulated MAI with historical reports
174 from the pre-vaccine era³⁷, which ranged from 24 months to 72 months (Supplementary Table
175 2). We grouped the MAI into three transmission levels: 48–72 months (low-transmission level),
176 36–48 months (medium-transmission level), and 24–36 months (high-transmission level).
177 Based on the evidence of age heterogeneities in transmissibility^{38,39}, we incorporated a
178 parameter (q) representing the transmissibility of <5-year-olds relative to ≥ 5 -year-olds. Finally,
179 for a range of fixed R_0 values in the interval 10–20, we calibrated q by fitting the predicted

180 pre-vaccine MAI to 3 MAI target values (lower bound, mid-value, and upper bound) in each
181 transmission level. For each target MAI, 5 R_0 — q pairs were selected, resulting in a total of 15
182 pairs for each transmission level.

183

184 The model was run assuming a constant population of 10 million for 500 years, at which point
185 convergence to the equilibrium solution was determined by the magnitude of the derivatives⁴⁰.

186 If this convergence criterion was not fulfilled, the final 20 years of the simulation were
187 extracted, and a linear model fit to the modeled cases. The simulation was judged to have
188 converged if the slope of the linear model was less than 10^{-3} per day, corresponding to a
189 change of <1 case per year. If convergence was achieved, the modeled MAI was calculated and
190 compared against the target MAI using the sum of squares.

191

192 The optimal age to recommend MCV1

193 We simulated recommending MCV1 at different ages, monthly from 6 to 20 months. For each
194 recommended age, we calculated the corresponding annual incidence at equilibrium, then
195 identified the MCV1 age that minimized the incidence aggregated over all age groups.
196 Furthermore, to identify factors that have the greatest impact on the optimal age we varied
197 these factors across realistic values (Figure 1b).

198

199 We simulated measles annual incidence using the model described above, simulating without
200 vaccination for 50 years, then introducing vaccination and running the model for a further 950
201 years. Vaccination was modeled as beginning from the recommended MCV1 age, with delays
202 in MCV1 and MCV2 following the delay distributions described above. The vaccine coverage
203 was defined as the proportion of a birth cohort vaccinated by 24 months after the recommended
204 MCV dose age. Based on reported MCV coverages from the WHO¹⁴, we set MCV1 coverage

205 at 45%, 55%, 65%, 75%, and 85%, and MCV2 coverage at 5% points lower than the set MCV1
206 coverage.

207

208 To assess variation in optimal ages, we estimated the optimal age for every combination of
209 SCM (China, India, Japan, Moscow, South Africa, UK, USA), vaccine coverage (MCV1
210 coverages: 45%, 55%, 65%, 75%, 85%), delay distribution (short delay and long delay), VE
211 curve (2.5%, 25%, 75%, 97.5% quantiles, and the MLE), and transmission level (low-,
212 medium-, and high-transmission, with 15 R_0 - q pairs for each level), see Figure 1b. Any
213 combination that failed to converge to the equilibrium solution according to the
214 abovementioned convergence criteria, at any recommended MCV1 age, was removed. Optimal
215 ages were then calculated and compared. To facilitate this comparison and evaluate the current
216 WHO clustering of recommendations, we clustered (using PAM clustering²⁹ based on
217 Euclidean distance, and the silhouette method³⁰ to determine cluster sizes) the estimated
218 optimal ages to identify groups of SCM.

219

220 Numerical Implementation

221 Analysis was carried out using R version 4.1.1⁴¹, using the R package “tidyverse”⁴². Partial
222 correlations were calculated using the package “ppcor”⁴³. SCAMs were fitted using the
223 package “scam”⁴⁴. Lomax distributions were fitted using the R package “optim”⁴⁵, using the
224 algorithm “L-BFGS-B”⁴⁶. PAM clustering was carried out using the R packages “cluster”⁴⁷
225 and “factoextra”⁴⁸. The measles model was implemented in C and R, using the R package
226 “pomp”⁴⁹. Parameter fitting was carried out using the subplex algorithm⁵⁰, in the R package
227 “nloptr”⁵¹. Mixed-effect models were fitted using the package “lme4”⁵². Figures were created
228 using the R packages “ggplot2”⁵³, “viridis”⁵⁴, “wesanderson”⁵⁵, “patchwork”⁵⁶, and “ggh4x”⁵⁷.

229

230

231 **Results:** (1242 words)

232 MCV1 effectiveness increases with age of receipt

233 After applying our inclusion criteria, we analyzed a total of 52 VE estimates from 16 studies.

234 As shown in Figure 3a, the point estimates and the confidence intervals of VE varied greatly.

235 Lower ages displayed particularly high variation in VE estimates. A large part of the overall

236 variation was captured by the SCAM (59.3% of deviance explained), which estimated an

237 increase in VE with age, confirming the results of the earlier meta-analysis⁹. The SCAM

238 estimated the VE at 64.5% at 6 months, approaching 100% by 20 months. Hence, the model

239 confirms that, for infants ≤ 20 months, the effectiveness of MCV1 increases with age of receipt.

240

241 Empirical data on the reported age of vaccination reveal MCV1 is frequently delayed

242 Based on data from 43 countries that met our inclusion criteria, we found that delays in

243 receiving MCV1 were prevalent (median (range) of median delay: 0.6 (0.1, 1.3) months),

244 exceeding 3 months for 25% of infants in 9 countries (median (range) of 75% delay quantile:

245 1.8 (0.4, 5.6) months).

246

247 In 41 of the 43 countries, we successfully fitted the Lomax distribution (see Supplementary

248 Figure 2), which recapitulated the 50% and 75% quantiles of the observed delay distributions.

249 Using PAM clustering, we identified two broad groups of countries (Figure 2b, Supplementary

250 Figure 2): one group with longer right tails (long delay, 35 countries, medoid country: Uganda,

251 survey median (IQR): 0.6 (0, 2.2) months, model median (IQR): 0.6 (0.2, 2.2) months) and

252 another group with shorter right tails (short delay, 5 countries, medoid country: Turkey, survey

253 median (IQR): 0.7 (0.2, 1.6) months, model median (IQR): 0.7 (0.2, 1.6) months). For both

254 clusters and all observed countries, the estimated parameters resulted in median delays in the

255 range 0.1 to 1.3 months, corresponding to a median delay of up to 14% when MCV1 was
256 recommended at 9 months. Taken together, this analysis indicates MCV1 is frequently delayed,
257 with important implications for measles control by vaccination, modeling the transmission
258 dynamics of measles, and estimating the optimal age of MCV1.

259

260 By combining the delay distribution with age-specific MCV1 effectiveness, we calculated the
261 cumulative effective vaccine coverage, defined as the proportion of a birth cohort protected by
262 the vaccine by a given age (Figure 2c). This effective coverage reflected the conceptual trade-
263 off in risks outlined in Figure 1a: increasing the recommended MCV1 age left a birth cohort
264 susceptible to infection for longer but also increased MCV1 effectiveness and, hence, the long-
265 term proportion of the cohort protected. Furthermore, the delay distribution also determined
266 the effective coverage, with longer delays resulting in lower proportions of a birth cohort
267 protected 18 months after the recommended age (Figure 2d).

268

269 Heterogeneity in transmissibility is necessary to recapitulate pre-vaccine reports of measles

270 MAI

271 When comparing model-derived MAIs to historical estimates in the pre-vaccine era, we found
272 that, for typically reported values of R_0 ⁵⁸ between 12 and 18, the model failed to recapitulate
273 the MAIs for multiple SCMs (Supplementary Figure 5). However, once age-specific
274 transmissibility was included, the transmission model could recapitulate all historical estimates
275 of MAIs for all SCMs, except the Chinese SCM for a MAI of 24 months. All fitted values of
276 q and R_0 converged according to the convergence criteria. These fitted pairs displayed a
277 negative association, such that increases in R_0 were compensated by decreases in q . Hence,
278 this calibration allowed us to define parameter regions that reproduce each transmission level
279 (Figure 4) for inclusion in the transmission model.

280

281 The optimal age to recommend MVC1 is sensitive to transmission level, contact structure, and
282 vaccine coverage

283 Of all the parameter sets modeled, 99.4% fulfilled our convergence criteria. Across those, we
284 identified a unique optimal age ranging between scenarios from 6 to 20 months. Furthermore,
285 the predicted optimal ages varied greatly between scenarios (see Figure 5a-b). For example,
286 the optimal age for the low-transmission level with the China SCM at 85% MVC1 coverage
287 ranged from 15 to 20 months, whereas the high-transmission level at 45% vaccine coverage
288 with the South Africa SCM ranged from 6 to 7 months. Moreover, recommending a non-
289 optimal MVC1 age on incidence could result in up to a 2.6-fold increase in incidence, although
290 the impact of an age mismatch was similarly scenario-dependent (see Figure 5a, Table 1).

291

292 Of the factors we varied, the transmission level impacted the optimal age the most. At 45%
293 MVC1 coverage, parameterized with the USA SCM, the optimal age ranged between 11 to 13
294 months in a low-transmission setting and 7 to 9 months in a high-transmission setting. More
295 generally, increasing transmission from low to medium decreased the optimal age by an
296 average of 1.6 months, and increasing from low to high transmission resulted in an average
297 decrease of 3.6 months (Supplementary Table 3). Higher transmission resulted in lower MAIs
298 and increased the risk of infection at younger ages, thus resulting in younger optimal ages to
299 compensate for this risk. Accordingly, increases in the pre-vaccine MAIs resulted in increases
300 in the optimal age (Supplementary Figure 6a). After controlling for the MAI, the additional
301 impact of R_0 and q on the optimal age was minimal (data not shown).

302

303 Social contact structure also affected the optimal age to recommend MVC1. Even after
304 controlling for transmission level and vaccine coverage, the range of optimal ages varied

305 between SCMs: for example, from 6 to 7 months for the South Africa SCM to 9 to 12 months
306 for the China SCM for a scenario with high transmission at 45% coverage. Depending on the
307 MCV coverage–transmission level scenario considered, the optimal ages clustered into 2–5
308 groups. However, ≥ 3 groups were typically required to capture the heterogeneity in optimal
309 ages between SCMs (13/15 scenarios, Supplementary Figure 7). In most scenarios, the China
310 SCM and the South Africa SCM tended to cluster independently, representing the SCMs with
311 the oldest and youngest optimal ages respectively, with other SCMs clustering together, with
312 optimal ages between these groups.

313

314 Finally, vaccine coverage also impacted the optimal age. Specifically, increased coverage
315 reduced measles incidence, resulting in higher optimal ages. For example, optimal MCV1 ages
316 in a low-transmission setting with the South Africa SCM ranged from 7 to 11 months at 45%
317 vaccine coverage and from 11 to 15 months at 85% vaccine coverage. In general, when
318 accounting for transmission level and SCM, a 10-percentage point increase in MCV1 coverage
319 resulted in an average increase in optimal age of 0.8 months (Supplementary Table 4). Overall,
320 these results demonstrate the importance of location-specific factors of measles epidemiology
321 for vaccine policy.

322

323 The impact of variations in age-specific MCV1 effectiveness and delay distribution on the
324 optimal age is minor

325 Uncertainty in the vaccine effectiveness curve only marginally affected the optimal age. When
326 holding all other parameters constant, varying the curve resulted in changes in the optimal age
327 in only 12.0% of parameter sets. In cases where the optimal age varied, the effect was
328 inconsistent, but generally, as the quantile of the VE curve increased, the optimal age decreased
329 (Supplementary Figure 6b).

330

331 Uncertainty in the MCV delay distribution had a similarly minor impact on optimal age. When
332 holding all other parameters fixed, changing the delay distribution resulted in a change in
333 optimal age in only 14.6% of parameter sets. When changes occurred, a higher optimal age
334 was predicted for the short delay distribution (Supplementary Figure 6c).

335

336 **Discussion:** (1057 words)

337 In this study, we developed a new method, based on a mechanistic model of measles
338 transmission and vaccination, to estimate the optimal age to recommend MCV1. In particular,
339 this model captured several complexities of measles epidemiology, including age-specific
340 contacts, vaccination delays, and VE variations with age of receipt. For every scenario tested,
341 we could identify a unique optimal age in the range of 6–20 months, contrasting the two ages
342 recommended by the WHO. Moreover, we found that the optimal age was governed by
343 location-specific factors, namely transmission level, vaccine coverage, and social contact
344 structure. Overall, our results suggest that, in addition to increasing vaccine coverage, adjusting
345 the recommended vaccination age could help minimize immunity gaps and reduce measles
346 incidence, taking steps toward eventual elimination from endemic settings.

347

348 A key result from our study is that the optimal age to recommend MCV1 may depend on the
349 local epidemiology of measles. Specifically, we predict that populations suffering from higher
350 measles transmission require a lower vaccination age. More generally, the impact of certain
351 factors of local epidemiology can be understood by considering their effect on the MAI and
352 transmission after vaccine introduction. This explains the effect of pre-vaccination
353 transmission levels (controlled by the parameters R_0 and q), which are correlated with post-
354 vaccination transmission levels. Similarly, increasing vaccination coverage is dynamically

355 equivalent to reducing transmission⁵⁹, hence resulting in higher optimal ages. However, even
356 at fixed transmission levels, the impact of social contact structure was strong. This result shows
357 that, in addition to broad metrics quantifying the transmission of measles, detailed knowledge
358 of social contact structure, quantified by data-derived SCMs, is needed to identify the optimal
359 in a given population.

360

361 In our simulations, two transmission parameters were required to recapitulate the range of
362 transmission intensities (quantified by the MAI) observed in the pre-vaccine era. Unlike earlier
363 modeling studies^{60,61}, varying only the basic reproduction number was insufficient to reach
364 target MAIs for all contact matrices. This discrepancy may be explained by the high age
365 resolution and the inclusion of realistic SCMs in our model. More generally, this result suggests
366 age heterogeneities beyond social contacts are necessary for the design of realistic models of
367 measles. Here, we allowed the relative transmissibility of <5 year olds to vary, and calibrated
368 values varied across multiple orders of magnitude (range: 0.005–46.3). This heterogeneity
369 could also be interpreted as a correction to the SCM, as the SCMs used were derived for more
370 modern populations than the pre-vaccine MAI estimates.

371

372 As the main goal of our study was to establish a proof of concept, we chose the minimization
373 endpoint of equilibrium incidence to estimate the optimal age in endemic settings. In real-world
374 applications, however, this endpoint should be defined over shorter time scales, reflecting the
375 time frame of control, and should be reassessed frequently as the optimal ages change with
376 decreasing transmission. Additionally, other endpoints like hospitalization or deaths may be
377 considered but will require extending our model to represent additional mechanisms of vaccine
378 protection, such as reduced disease severity in vaccine-breakthrough cases⁶². Importantly,
379 considering other endpoints may change the nature of the trade-off in risks, in particular

380 because of the increased incentive to vaccinate early if mortality is increased in younger ages⁶³.
381 Similarly, other endpoints, like the risk of invasion, will be needed to estimate the optimal age
382 in elimination settings, where vulnerability to outbreaks may persist due to residual pockets of
383 susceptible individuals⁶⁴. Applying our model in such settings will require a stochastic
384 formulation, due to the low number of cases and frequent extinctions that deterministic models
385 cannot capture well.

386
387 Furthermore, the real-world application of our method will require additional components
388 beyond population-specific information on the SCM, vaccine coverage, and delay distribution,
389 to fully characterize measles epidemiological dynamics in a target population. These include
390 demography, as changes in population structure are expected to affect age-specific
391 transmission dynamics⁶⁵, with more circulation expected in younger populations⁶⁶. A second
392 key component is seasonality in transmission, which can result from term-time increases in
393 contacts among school-aged children⁶⁷ or the effect of climate on virus transmissibility⁶⁸.
394 Therefore, a prerequisite to applying our method is a detailed model—identified, for example,
395 by fitting to long-term incidence data using modern statistical inference techniques⁴⁹—for
396 capturing the local drivers of measles transmission.

397
398 Another key consideration when applying our proposed method is SIAs. These additional
399 immunization campaigns aim to rapidly increase population immunity by vaccinating target
400 demographics—typically children aged ≤ 14 years—regardless of vaccination history⁶⁹. In
401 general, such campaigns are expected to reduce transmission and, thus, increase the optimal
402 age for MCV1. Hence, in settings where SIAs are routinely administered, MCV1 age should
403 be optimized to maximize the effect of both interventions.

404

405 Beyond the components listed above, our method could be extended to consider the effects of
406 MCVs on other pathogens. Indeed, measles infection can cause immune amnesia, whereby the
407 suppression of immune cells partially erases immune memory to previously encountered
408 pathogens⁷⁰. As a result, MCVs have beneficial indirect effects on other infectious diseases⁷¹.
409 In addition, it has been proposed that MCVs directly affect non-measles pathogens, perhaps
410 because of enhanced trained immunity⁷². Beyond MCVs, our proposed method could also be
411 applied to estimate the optimal age for vaccines against other childhood infections. We expect
412 the relationship between vaccination age and VE to be qualitatively similar for other vaccines,
413 even though the empirical evidence has remained more limited than for measles^{73,74}. As the
414 measles vaccine is often combined with the mumps and rubella vaccines (MMR), the natural
415 next candidates would be these two vaccines. Because mumps and rubella infection have
416 different transmissibility than measles (Mumps R_0 : 4–7⁷⁵ , Rubella R_0 : 6–7⁷⁵), the risk trade-
417 off underlying the optimal age is expected to differ. Hence, a future research question is how
418 to extend our approach to identify the optimal age for combined vaccines.

419

420 Despite the availability of effective vaccines for over 60 years, measles remains a considerable
421 threat in many countries. Here, we propose that, alongside ever-necessary efforts to increase
422 vaccine coverage, another effective intervention to reduce measles cases may be to tailor the
423 vaccination age. Hence, our results suggest the scope for public health authorities to improve
424 measles control and reach for eventual elimination by customizing the recommended
425 vaccination schedule. More generally, as the trade-off underlying the optimal age is not specific
426 to measles, our results could have ramifications for controlling many other vaccine-preventable
427 diseases.

428

429 **References:**

- 430 1. Paules, C. I., Marston, H. D. & Fauci, A. S. Measles in 2019 — Going Backward. *N. Engl.*
431 *J. Med.* **380**, 2185–2187 (2019).
- 432 2. Wang, R., Jing, W., Liu, M. & Liu, J. Trends of the Global, Regional, and National
433 Incidence of Measles, Vaccine Coverage, and Risk Factors in 204 Countries From 1990 to
434 2019. *Front. Med.* **8**, (2022).
- 435 3. Langmuir, A. D. Medical Importance of Measles. *Am. J. Dis. Child.* **103**, 224–226 (1962).
- 436 4. Dixon, M. G. *et al.* Progress Toward Regional Measles Elimination — Worldwide, 2000–
437 2020. *Morb. Mortal. Wkly. Rep.* **70**, 1563–1569 (2021).
- 438 5. World Health Organization. Measles fact sheet. *World Health Organization*
439 <https://www.who.int/news-room/fact-sheets/detail/measles> (2023).
- 440 6. World Health Organization. Measles and rubella strategic framework 2021-2030. *Measles*
441 *and rubella strategic framework: 2021-2030* [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/measles-and-rubella-strategic-framework-2021-2030)
442 [redirect/measles-and-rubella-strategic-framework-2021-2030](https://www.who.int/publications-detail-redirect/measles-and-rubella-strategic-framework-2021-2030) (2020).
- 443 7. Causey, K. *et al.* Estimating global and regional disruptions to routine childhood vaccine
444 coverage during the COVID-19 pandemic in 2020: a modelling study. *The Lancet* **398**,
445 522–534 (2021).
- 446 8. World Health Organization. Measles - Reported cases by country. *Global Health*
447 *Observatory data repository* https://apps.who.int/gho/data/view.main.1540_62?lang=en
448 (2021).
- 449 9. Hughes, S. L. *et al.* The effect of time since measles vaccination and age at first dose on
450 measles vaccine effectiveness – A systematic review. *Vaccine* **38**, 460–469 (2020).
- 451 10. Gans, H. *et al.* Measles and mumps vaccination as a model to investigate the
452 developing immune system: passive and active immunity during the first year of life.
453 *Vaccine* **21**, 3398–3405 (2003).

- 454 11. Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in
455 humans from infancy to old age. *Proc. R. Soc. B Biol. Sci.* **282**, 20143085 (2015).
- 456 12. McLean, A. R. & Anderson, R. M. Measles in developing countries Part I.
457 Epidemiological parameters and patterns. *Epidemiol. Infect.* **100**, 111–133 (1988).
- 458 13. Mclean, A. R. & Anderson, R. M. Measles in developing countries. Part II. The
459 predicted impact of mass vaccination. *Epidemiol. Infect.* **100**, 419–442 (1988).
- 460 14. World Health Organisation. WHO Immunization Data portal.
461 https://immunizationdata.who.int/compare.html?COMPARISON=type1__WIISE/MT_AD
462 [_COV_LONG+type2__WIISE/MT_AD_INC_RATE_LONG+option1__MCV_coverage+](https://immunizationdata.who.int/compare.html?COMPARISON=type1__WIISE/MT_AD_INC_RATE_LONG+option1__MCV_coverage+option2__MEASLES_incidence&GROUP=Countries&YEAR=)
463 [option2__MEASLES_incidence&GROUP=Countries&YEAR=.](https://immunizationdata.who.int/compare.html?COMPARISON=type1__WIISE/MT_AD_INC_RATE_LONG+option1__MCV_coverage+option2__MEASLES_incidence&GROUP=Countries&YEAR=)
- 464 15. United Nations Development Program. *Human Development Reports: Data*
465 *downloads. Human Development Reports* [https://hdr.undp.org/data-center/documentation-](https://hdr.undp.org/data-center/documentation-and-downloads)
466 [and-downloads.](https://hdr.undp.org/data-center/documentation-and-downloads)
- 467 16. World Health Organisation. Vaccination schedule for Measles. *World Health*
468 *Organisation* [https://immunizationdata.who.int/pages/schedule-by-](https://immunizationdata.who.int/pages/schedule-by-disease/measles.html?ISO_3_CODE=&TARGETPOP_GENERAL=)
469 [disease/measles.html?ISO_3_CODE=&TARGETPOP_GENERAL=](https://immunizationdata.who.int/pages/schedule-by-disease/measles.html?ISO_3_CODE=&TARGETPOP_GENERAL=) (2021).
- 470 17. European Centre for Disease Prevention and Control. Measles: Recommended
471 vaccinations. *Vaccine Scheduler* [https://vaccine-](https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdByDisease=-1)
472 [schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdB](https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdByDisease=-1)
473 [yDisease=-1](https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdByDisease=-1) (2023).
- 474 18. Rochmyaningsih, D. Indonesian ‘vaccine fatwa’ sends measles immunization rates
475 plummeting. *Science News* [https://www.science.org/content/article/indonesian-vaccine-](https://www.science.org/content/article/indonesian-vaccine-fatwa-sends-measles-immunization-rates-plummeting)
476 [fatwa-sends-measles-immunization-rates-plummeting](https://www.science.org/content/article/indonesian-vaccine-fatwa-sends-measles-immunization-rates-plummeting) (2018).
- 477 19. Ministerio de Salud y Deportes de Bolivia. Esquema Nacional de Vacunación 2018.
478 *Ministerio de Salud y Deportes* [https://www.minsalud.gob.bo/es/42-pai/3067-esquema-de-](https://www.minsalud.gob.bo/es/42-pai/3067-esquema-de)

- 479 vacunacion (2018).
- 480 20. Centers for Disease Control and Prevention. About Measles Vaccination | CDC.
481 *Vaccines and Preventable Diseases* <https://www.cdc.gov/vaccines/vpd/measles/index.html>
482 (2022).
- 483 21. Public Health Agency of Canada. Recommended immunization schedules: Canadian
484 Immunization Guide. [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-13-recommended-immunization-schedules.html)
485 health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-
486 immunization-information/page-13-recommended-immunization-schedules.html (2007).
- 487 22. UNICEF. Know your child’s immunization schedule | UNICEF India. *UNICEF India*
488 <https://www.unicef.org/india/know-your-childs-immunization-schedule>.
- 489 23. KDCA. KDCA. *KDCA* <https://www.kdca.go.kr>.
- 490 24. Chapter 6: Choosing effect measures and computing estimates of effect. in *Cochrane*
491 *Handbook for Systematic Reviews of Interventions version 6.4* (eds. Julian PT Higgins,
492 Tianjing Li, & Jonathan J Deeks) (Cochrane, 2023).
- 493 25. Pya, N. & Wood, S. N. Shape constrained additive models. *Stat. Comput.* **25**, 543–559
494 (2015).
- 495 26. Ruppert, D., Wand, M. P. & Carroll, R. J. *Semiparametric Regression*. (Cambridge
496 University Press, 2003).
- 497 27. Clark, A. & Sanderson, C. Timing of children’s vaccinations in 45 low-income and
498 middle-income countries: an analysis of survey data. *The Lancet* **373**, 1543–1549 (2009).
- 499 28. Lomax, K. S. Business Failures: Another Example of the Analysis of Failure Data. *J.*
500 *Am. Stat. Assoc.* **49**, 847–852 (1954).
- 501 29. Leonard Kaufman & Peter J. Rousseeuw. Partitioning Around Medoids (Program
502 PAM). in *Finding Groups in Data* 68–125 (John Wiley & Sons, Ltd, 1990).
503 doi:10.1002/9780470316801.ch2.

- 504 30. Kaufman, L. & Rousseeuw, P. J. *Finding Groups in Data*. (John Wiley & Sons, Inc.,
505 2005).
- 506 31. Tibshirani, R., Walther, G. & Hastie, T. Estimating the number of clusters in a data
507 set via the gap statistic. *J. R. Stat. Soc. Ser. B Stat. Methodol.* **63**, 411–423 (2001).
- 508 32. Bjørnstad, O. N., Finkenstädt, B. F. & Grenfell, B. T. Dynamics of Measles
509 Epidemics: Estimating Scaling of Transmission Rates Using a Time Series Sir Model.
510 *Ecol. Monogr.* **72**, 169–184 (2002).
- 511 33. Grenfell, B. T., Bjørnstad, O. N. & Finkenstädt, B. F. Dynamics of Measles
512 Epidemics: Scaling Noise, Determinism, and Predictability with the Tsir Model. *Ecol.*
513 *Monogr.* **72**, 185–202 (2002).
- 514 34. Mistry, D. *et al.* Inferring high-resolution human mixing patterns for disease
515 modeling. *Nat. Commun.* **12**, 323 (2021).
- 516 35. Mossong, J. *et al.* Social Contacts and Mixing Patterns Relevant to the Spread of
517 Infectious Diseases. *PLOS Med.* **5**, e74 (2008).
- 518 36. Verguet, S. *et al.* Controlling measles using supplemental immunization activities: A
519 mathematical model to inform optimal policy. *Vaccine* **33**, 1291–1296 (2015).
- 520 37. Anderson, R. & May, R. Vaccination against rubella and measles: Quantitative
521 investigations of different policies. *J. Hyg. (Lond.)* **90**, 259–325 (1983).
- 522 38. Galanti, M. *et al.* Rates of asymptomatic respiratory virus infection across age groups.
523 *Epidemiol. Infect.* **147**, e176 (2019).
- 524 39. Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-
525 19 epidemics. *Nat. Med.* **26**, 1205–1211 (2020).
- 526 40. Soetaert, K., Petzoldt, T. & Setzer, R. W. Solving Differential Equations in R:
527 Package deSolve. *J. Stat. Softw.* **33**, 1–25 (2010).
- 528 41. R Core Team. R: A Language and Environment for Statistical Computing. (2022).

- 529 42. Wickham, H. *et al.* Welcome to the Tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).
- 530 43. Kim, S. ppcor: Partial and Semi-Partial (Part) Correlation. (2015).
- 531 44. Pya, N. scam: Shape Constrained Additive Models. (2022).
- 532 45. Nocedal, J. & Wright, S. J. *Numerical Optimization*. (Springer, 2006).
- 533 46. Byrd, R. H., Lu, P., Nocedal, J. & Zhu, C. A Limited Memory Algorithm for Bound
534 Constrained Optimization. *SIAM J. Sci. Comput.* **16**, 1190–1208 (1995).
- 535 47. Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M. & Hornik, K. cluster: Cluster
536 Analysis Basics and Extensions. [https://cran.r-](https://cran.r-project.org/web/packages/cluster/citation.html)
537 [project.org/web/packages/cluster/citation.html](https://cran.r-project.org/web/packages/cluster/citation.html) (2022).
- 538 48. Kassambara, A. & Mundt, F. factoextra: Extract and Visualize the Results of
539 Multivariate Data Analyses. (2020).
- 540 49. King, A. A., Nguyen, D. & Ionides, E. L. Statistical Inference for Partially Observed
541 Markov Processes via the R Package pomp. *J. Stat. Softw.* **69**, 1–43 (2016).
- 542 50. Rowan, T. Functional stability analysis of numerical algorithms. in (1990).
- 543 51. NLOpt - NLOpt Documentation. <https://nlopt.readthedocs.io/en/latest/>.
- 544 52. Bates, D. *et al.* lme4: Linear Mixed-Effects Models using ‘Eigen’ and S4. (2022).
- 545 53. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlang, 2016).
- 546 54. Garnier, S. *et al.* sjmgarnier/viridis: viridis 0.6.0 (pre-CRAN release). (2021)
547 doi:10.5281/zenodo.4679424.
- 548 55. Ram, K., Wickham, H., Richards, C. & Baggett, A. wesanderson: A Wes Anderson
549 Palette Generator. (2018).
- 550 56. Pedersen, T. L. patchwork: The Composer of Plots. (2022).
- 551 57. Brand, T. van den. ggh4x: Hacks for ‘ggplot2’. (2023).
- 552 58. Guerra, F. M. *et al.* The basic reproduction number (R0) of measles: a systematic
553 review. *Lancet Infect. Dis.* **17**, e420–e428 (2017).

- 554 59. Earn, D. J. D., Rohani, P., Bolker, B. M. & Grenfell, B. T. A Simple Model for
555 Complex Dynamical Transitions in Epidemics. *Science* **287**, 667–670 (2000).
- 556 60. Magpantay, F. M. G., King, A. A. & Rohani, P. Age-structure and transient dynamics
557 in epidemiological systems. *J. R. Soc. Interface* **16**, 20190151 (2019).
- 558 61. Farrington, C. P., Kanaan, M. N. & Gay, N. J. Estimation of the Basic Reproduction
559 Number for Infectious Diseases from Age-Stratified Serological Survey Data. *J. R. Stat.*
560 *Soc. Ser. C Appl. Stat.* **50**, 251–292 (2001).
- 561 62. Fappani, C. *et al.* Breakthrough Infections: A Challenge towards Measles
562 Elimination? *Microorganisms* **10**, 1567 (2022).
- 563 63. Sbarra, A. N. *et al.* Estimating national-level measles case–fatality ratios in low-
564 income and middle-income countries: an updated systematic review and modelling study.
565 *Lancet Glob. Health* **11**, e516–e524 (2023).
- 566 64. Kohonen, M. *et al.* Diagnostic challenges and pockets of susceptibility identified
567 during a measles outbreak, Luxembourg, 2019. *Eurosurveillance* **26**, 2000012 (2021).
- 568 65. Graham, M. *et al.* Measles and the canonical path to elimination. *Science* **364**, 584–
569 587 (2019).
- 570 66. Geard, N. *et al.* The effects of demographic change on disease transmission and
571 vaccine impact in a household structured population. *Epidemics* **13**, 56–64 (2015).
- 572 67. Keeling, M. J. & Rohani, P. *Modeling Infectious Diseases in Humans and Animals.*
573 *Modeling Infectious Diseases in Humans and Animals* (Princeton University Press, 2011).
574 doi:10.1515/9781400841035.
- 575 68. de Jong, J. G. The survival of measles virus in air, in relation to the epidemiology of
576 measles. *Arch. Für Gesamte Virusforsch.* **16**, 97–102 (1965).
- 577 69. World Health Organization. Planning and implementing high-quality supplementary
578 immunization activities for injectable vaccines using an example of measles and rubella

- 579 vaccines: field guide. <https://www.who.int/publications-detail-redirect/9789241511254>
580 (2016).
- 581 70. Mina, M. J. *et al.* Measles virus infection diminishes preexisting antibodies that offer
582 protection from other pathogens. *Science* **366**, 599–606 (2019).
- 583 71. Mina, M. J., Metcalf, C. J. E., de Swart, R. L., Osterhaus, A. D. M. E. & Grenfell, B.
584 T. Long-term measles-induced immunomodulation increases overall childhood infectious
585 disease mortality. *Science* **348**, 694–699 (2015).
- 586 72. Aaby, P. *et al.* The optimal age of measles immunisation in low-income countries: a
587 secondary analysis of the assumptions underlying the current policy. *BMJ Open* **2**,
588 e000761 (2012).
- 589 73. Galil, K., Fair, E., Mountcastle, N., Britz, P. & Seward, J. Younger Age at
590 Vaccination May Increase Risk of Varicella Vaccine Failure. *J. Infect. Dis.* **186**, 102–105
591 (2002).
- 592 74. Redd, S. C. *et al.* Comparison of Vaccination with Measles-Mumps-Rubella Vaccine
593 at 9, 12, and 15 Months of Age. *J. Infect. Dis.* **189**, S116–S122 (2004).
- 594 75. Emilia Vynnycky & Richard G White. An introduction to infectious disease
595 modelling – EMILIA VYNNYCKY and RICHARD G WHITE.
596 <https://anintroductiontoinfectiousdiseasemodelling.com/>.
597

598 **Data availability / Code availability:**

599 Code will be deposited in the Open Research Data Repository of the Max Planck Society,
600 Edmond (<https://edmond.mpg.de>), before publishing.

601

602 **Acknowledgements:**

603 This work was supported by the Max Planck Society (Berlin, Germany). Computations were
604 performed at the Max Planck Computing and Data Facility (MPCDF). We thank Professor
605 Pejman Rohani for his valuable feedback on the manuscript.


606

607 **Author contributions:**

608 EG and MDdC conceptualized the project, and designed the methods. Implementation was
609 carried out by EG, and reviewed by LABG. EG and MDdC wrote the manuscript, with support
610 from MB and LABG. MDdC supervised the project.

611

612 **Figures:**



613

614 **Figure 1: Trade-off in risks and resulting framework for calculating the optimal age to**

615 **recommend MCV1.** a) Illustration of the risk trade-off that should be balanced when


616 recommending MCV1 age. b) Conceptual framework for calculating the optimal age to

617 recommend MCV1. Gray boxes indicate variables used to parameterize the mechanistic model

618 of measles transmission and vaccination. Values in brackets indicate the number of variants

619 used. The yellow dots and box reflect incidence, the blue arrow and line the minimization of


620 the incidence, and red indicates the age at minimum incidence, the optimal age.



621

622 **Figure 2: Map and distribution of recommended MCV1 ages.** Reported recommended
623 MCV1 ages by country, from the WHO¹⁶, ECDC¹⁷, and country-based reporting¹⁸⁻²³. The
624 histogram indicates the number of countries recommending MCV1 vaccination at each age.

625



626

627 **Figure 3: The impact of recommended MCV1 age on the effective vaccine coverage.** a)

628 MCV1 effectiveness with age of receipt. VE estimates are indicated with points, with vertical

629 lines indicating the 95% confidence interval and horizontal lines indicating uncertainty in

630 MCV1 age. The SCAM model is indicated in gray; the shaded area indicates the approximate

631 simultaneous 95% confidence interval, and the lines indicate the 2.5%, 25%, MLE, 75%, and

632 97.5% quantiles. b) Cumulative delay distributions. Cluster medoids are bolded, with points

633 showing the associated delay data. c) Cumulate effective MCV1 coverage when recommending

634 MCV1 at 6, 9, and 12 months, with long delay distribution. Cumulative vaccine coverage after

635 24 months is set to 100%. Dashed lines indicate the MCV1 coverage, points indicate the


636 effective MCV1 coverage, with vertical lines indicating the 95% confidence intervals. d)

637 Cumulative effective MCV1 coverage at 18 months when recommending MCV1 at 6, 9, and

638 12 months, for long and short delay distributions. Points indicate MLE estimates, and vertical

639 lines indicate the 95% confidence intervals.

640



641

642 **Figure 4: Basic reproductive number and relative <5 years transmissibility for 7 social**


643 **contact matrices.** For each SCM, the left-hand plots show the social contact rate between age

644 groups. In the corresponding right-hand plots, points indicate the fitted values of R_0 and q for

645 each target MAI, with larger points indicating the values selected to parameterize the

646 mechanistic model. Transmission levels are indicated by point shape. For clarity, medium-

647 transmission level points are not shown.



648

649 **Figure 5: Estimating the optimal age to recommend measles vaccination.** a) Estimated
 650 annual incidence when recommending MCV1 at ages 6–20 months, with 45% MCV1
 651 coverage. Each line indicates the relative incidence for a given parameter set, relative to the
 652 minimum incidence for that parameter set. b) Heatmap of optimal ages. Opacity indicates the
 653 proportion of parameter sets with an optimum in a given MCV1 age. For clarity, the results for
 654 55% and 75% vaccination coverage are not displayed.

655

656 **Tables:**

SCM	Optimal age	Incidence at the optimal age	% Increased incidence		
			9 months	12 months	
China	10 (9, 12)	747 (729, 766)	0 (0, 1)	0 (0, 1)	High transmission, 45% MCV1 coverage
India	7 (6, 8)	823 (796, 856)	1 (0, 2)	4 (3, 7)	
Japan	9 (7, 10)	784 (752, 824)	0 (0, 1)	2 (1, 4)	
Moscow	9 (7, 10)	782 (754, 815)	0 (0, 1)	2 (1, 4)	
South Africa	6 (6, 7)	846 (820, 876)	2 (1, 3)	6 (4, 8)	
UK	7 (6, 8)	814 (782, 852)	1 (0, 2)	5 (3, 8)	
USA	8 (7, 9)	796 (766, 832)	0 (0, 1)	3 (1, 5)	
China	17 (15, 20)	169 (124, 196)	15 (8, 30)	4 (2, 11)	Low transmission, 85% MCV1 coverage
India	13 (11, 15)	205 (159, 237)	7 (2, 14)	1 (0, 2)	
Japan	16 (14, 19)	173 (126, 203)	14 (7, 28)	4 (1, 10)	
Moscow	16 (13, 19)	174 (125, 208)	13 (6, 27)	3 (0, 11)	
South Africa	13 (11, 15)	206 (151, 244)	6 (1, 16)	1 (0, 3)	
UK	13 (12, 16)	190 (141, 223)	9 (3, 19)	1 (0, 4)	
USA	16 (13, 18)	181 (133, 212)	12 (6, 25)	3 (0, 8)	

657 **Table 1: Estimated optimal ages and annual incidences.** Optimal age indicates the mean
658 (95% confidence interval) of the optimal ages from all parameter sets for the scenario.
659 Incidence indicates the mean (95% confidence interval) annual incidence per 100,000 of the

660 parameter sets at the optimal ages. Percentage increased incidence reflects the mean of the
661 incidence increase compared to the optimal age incidence.